Biallelic inactivation of BAP1 is observed in uveal melanoma, lung adenocarcinoma and meningioma.

Many tumors harboring BAP1 germline mutations were associated with BAP1 syndrome, including mesothelioma and ocular/cutaneous melanomas, as well as renal, breast, lung, gastric, and basal cell carcinomas.

Low BAP1 expression is associated with lung cancer progression.

Our cohort included 257 lung cancer patients, of which 155 (60%) were adenocarcinomas and 72 (28%) were squamous cell carcinomas, with no other subtype comprising more than 3%. BAP1 loss of expression was found in only one lung cancer. We conclude that BAP1 mutation occurs very infrequently (0.4%) in non-small cell lung cancer.

Loss of BAP1 expression is associated with lung adenocarcinoma.

Loss of BAP1 expression is a rare event in non-small cell lung cancer.